Brokerages predict that Spero Therapeutics Inc (NASDAQ:SPRO) will post ($1.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($0.92). Spero Therapeutics posted earnings of ($0.60) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 73.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($3.11) per share for the current fiscal year, with EPS estimates ranging from ($3.34) to ($2.94). For the next fiscal year, analysts forecast that the company will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Monday, November 4th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). Spero Therapeutics had a negative return on equity of 43.10% and a negative net margin of 287.11%. The business had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $2.03 million.

A number of brokerages have recently commented on SPRO. Cowen reissued a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, November 5th. HC Wainwright boosted their target price on Spero Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Janney Montgomery Scott initiated coverage on Spero Therapeutics in a research note on Monday, September 9th. They set a “buy” rating for the company. Zacks Investment Research cut Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Oppenheimer decreased their target price on Spero Therapeutics from $30.00 to $20.00 in a research note on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Spero Therapeutics has a consensus rating of “Buy” and a consensus price target of $23.50.

Hedge funds and other institutional investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of Spero Therapeutics during the first quarter worth approximately $39,000. Wells Fargo & Company MN raised its stake in shares of Spero Therapeutics by 187.9% during the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after purchasing an additional 8,915 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Spero Therapeutics by 9.2% during the second quarter. JPMorgan Chase & Co. now owns 164,389 shares of the company’s stock worth $1,826,000 after purchasing an additional 13,814 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Spero Therapeutics during the second quarter worth approximately $25,000. Finally, AWM Investment Company Inc. raised its stake in shares of Spero Therapeutics by 6.4% during the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock worth $6,887,000 after purchasing an additional 36,019 shares during the last quarter. Institutional investors own 50.98% of the company’s stock.

Spero Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $10.22. 21,200 shares of the stock traded hands, compared to its average volume of 26,086. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48. The stock has a market capitalization of $196.26 million, a price-to-earnings ratio of -3.93 and a beta of 2.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.90 and a quick ratio of 6.90. The firm’s 50 day moving average price is $10.67 and its 200-day moving average price is $10.93.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Article: Understanding Market Liquidity

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.